Reviewer’s report

**Title:** Study protocol of the TRICOLORE trial: A randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer

**Version:** 2  
**Date:** 11 December 2014

**Reviewer:** Lowell Hart

**Reviewer’s report:**

1. I would like to see evidence referenced that the two S1 regimens are equivalent in efficacy, the 2 week and 4 week regimens. I understand that they are commonly used in Japan, but are we assuming the TTP and response rate are the same. Otherwise the data may be hard to interpret in a study with four treatment regimens. I consider this to be a discretionary revision

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** Yes, but I do not feel adequately qualified to assess the statistics.

**Declaration of competing interests:**

I have had research funding and honoraria from Genentech who manufactures Bevacizumab, used in this trial. However the trial could not affect them financially since it is used in standard and research arms in the trial.